INSIGHTS #20: Barath and Radhika on the Healthcare Landscape in India episode artwork

EPISODE · Dec 7, 2018 · 31 MIN

INSIGHTS #20: Barath and Radhika on the Healthcare Landscape in India

from SeedToScale | Curated by Accel · host SeedToScale

We continue with the #INSIGHTSPodcast Series and in this episode, we focus on the healthcare sector and discuss opportunities and the market landscape using examples from the Accel portfolio. To talk about this exciting topic, We have Barath & Radhika, Principal & Sr Associate at Accel whose core focus investment areas are in Life sciences, Medtech and digital health. On this podcast, we discuss the healthcare landscape in India using examples from the Accel portfolio and what to look for while building out a healthcare company from India : Examples from Accel portfolio on problems being solved in healthcare for global markets Lifesciences What is life sciences - the model of an IP led lifesciences company solving global problems Mitra Biotech - Why did they choose to start in India? The solution to an age old problem - How do you understand the effects of drugs on tumors without bombarding a patient with the drugs Zumutor Building a platform to develop molecules for improving drug delivery to cancer cells Healthcare Delivery The problems with the healthcare delivery in India Moving care back to the home - counter intuitive insight and how Portea plugs the gaps in the delivery space Digital health Onco.com - using digital distribution to disrupt the current value chain and deliver better care for patients Using AI to deliver healthcare in the diagnostics space - How sigtuple uses digital distribution and AI to deliver healthcare and diagnose correctly. The Indian Advantage - Why healthcare is attractive in India Capital efficiency from being in India 3x-5x advantage in capital required from building from India Talent, Infrastructure arbitrage from India - The Indian pharma story for next wave of lifesciences Speeding things up - How India helps speed up development The regulatory advantage - lesser regulations for initial development of drugs Using the initial momentum and taking the drugs to more regulated markets for trials - the difficulty of trials in the Indian market Examples where the thesis on cost and time plays out The estimates from Axio - getting to market with 1/10th the capital and 60% of the time to get to market with a great product Setting the standards in India so the product goes global - no compromise on quality The healthcare business - things to consider while getting into the healthcare sector The trust process - building trust, and the time and effort it takes to build trust Importance of IP - having a good IP and using peer-reviewed publications for validation and marketing Patent portfolio and defensiblity of patents - defending incremental IP and not infringing existing patents, and filing patents to get it out in the world The team - building a team as the company grows, and the expertise required; the differences between life sciences, and non-life science businesses The Indian story - shift from communicable to chronic disease, infrastructure gap, mobile first country and the advantage technology provides in such an environment.

Episode metadata supplied by the publisher feed · Published Dec 7, 2018

Embed this episode

Ready to play

INSIGHTS #20: Barath and Radhika on the Healthcare Landscape in India

0:00 31:12

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of SeedToScale | Curated by Accel?

This episode is 31 minutes long.

When was this SeedToScale | Curated by Accel episode published?

This episode was published on December 7, 2018.

Can I download this SeedToScale | Curated by Accel episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!